Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Her2-Positive Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT03820063
What this trial is testing

Image-guided De-escalation of Neo-adjuvant Chemotherapy in HER2-positive Breast Cancer: the TRAIN-3 Study

Who this might be right for
Breast Cancer
Borstkanker Onderzoek Groep 462
Large-scale testing (Phase 3)Active Not RecruitingNCT01996267
What this trial is testing

Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2

Who this might be right for
Breast CancerHER2 Positive
The Netherlands Cancer Institute 437
Large-scale testing (Phase 3)Study completedNCT00073528
What this trial is testing

Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer

Who this might be right for
Breast Neoplasms
Novartis Pharmaceuticals 1,286
Early research (Phase 1)Ended earlyNCT05489679
What this trial is testing

AC682 In Chinese Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Accutar Biotechnology Inc 6
Testing effectiveness (Phase 2)Study completedNCT00736970
What this trial is testing

Oral Deforolimus With Trastuzumab for Patients With HER2-positive Trastuzumab-Refractory Metastatic Breast Cancer (8669-009)

Who this might be right for
Breast CancerBreast Neoplasms
Merck Sharp & Dohme LLC 34
Early research (Phase 1)UnknownNCT04460456
What this trial is testing

SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors

Who this might be right for
HER2 Positive Solid Tumors
Silverback Therapeutics 58
Early research (Phase 1)Study completedNCT00146172
What this trial is testing

Study Evaluating HKI-272 in Tumors

Who this might be right for
Breast Neoplasms
Puma Biotechnology, Inc. 73
Early research (Phase 1)Study completedNCT03620201
What this trial is testing

M7824 in Treating Patients With Stage II-III HER2 Positive Breast Cancer

Who this might be right for
Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8+11 more
M.D. Anderson Cancer Center 20
Testing effectiveness (Phase 2)Ended earlyNCT03289039
What this trial is testing

Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Dana-Farber Cancer Institute 21
Testing effectiveness (Phase 2)Study completedNCT02129556
What this trial is testing

Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast Cancer

Who this might be right for
Metastatic Breast Cancer
ETOP IBCSG Partners Foundation 58
Testing effectiveness (Phase 2)Active Not RecruitingNCT06428396
What this trial is testing

Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)

Who this might be right for
Metastatic Breast Cancer
Merck Sharp & Dohme LLC 120
Large-scale testing (Phase 3)Active Not RecruitingNCT04457596
What this trial is testing

T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

Who this might be right for
Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8HER2 Positive Breast Carcinoma+4 more
Alliance for Clinical Trials in Oncology 1,056
Not applicableLooking for participantsNCT07542496
What this trial is testing

Real-world Bicohort Observational Study of a Pertuzumab Biosimilar in the Treatment of Breast Cancer: in the Neoadjuvant Setting and in First-line Metastatic Disease

Who this might be right for
Breast CancerHer 2 Positive Breast Cancer
Société Algérienne de Formation et Recherche en Oncologie 1,000
Not applicableStudy completedNCT03719833
What this trial is testing

Sentinel Lymph Node Biopsy After Neoadjuvant Treatment in Breast Cancer Patents

Who this might be right for
Breast CancerSentinel Lymph Node BiopsyNeoadjuvant Chemotherapy
Clinical Hospital Center Rijeka 230
Large-scale testing (Phase 3)Active Not RecruitingNCT06065748
What this trial is testing

Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Who this might be right for
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Hoffmann-La Roche 1,050
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07801898
What this trial is testing

Neoadjuvant Endocrine Therapy Combined With Chemotherapy in ER-positive, HER2-negative Stage I-III Breast Cancer

Who this might be right for
Invasive Breast Cancer (Stage I-III)
The Second Hospital of Anhui Medical University 36
Testing effectiveness (Phase 2)Looking for participantsNCT06874933
What this trial is testing

Neoadjuvant Chemotherapy in Combination With Anlotinib and Benmelstobart for HR+/HER2- Breast Cancer (NEOTORCH-BREAST03)

Who this might be right for
HR+/HER2- Breast Cancer
First Affiliated Hospital of Zhejiang University 35
Testing effectiveness (Phase 2)Ended earlyNCT01953926
What this trial is testing

Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations

Who this might be right for
Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
Puma Biotechnology, Inc. 582
Testing effectiveness (Phase 2)WithdrawnNCT06105008
What this trial is testing

Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Neoplasms
RemeGen Co., Ltd.
Not applicableStudy completedNCT02269813
What this trial is testing

PRospective Study to Measure the Impact of MammaPrint on Adjuvant Treatment in Hormone Receptor-positive HER2-negative Breast Cancer Patients (PRIMe)

Who this might be right for
Breast Cancer
Women's Cancer Study Group GmbH 452
Next Page